



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PARKAR, et al.

Application No.: **10/747,994**


Filed: **December 30, 2003**

Title: **NUCLEIC ACID ENCODING A NOVEL
PROSTAGLANDIN RECEPTOR
PROTEIN AND METHODS OF USE
THEREOF**

Examiner: **Not Yet Known**

Art Unit: **Not Yet Known**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

22 January 2004
Date of Deposit

Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.


- (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626
Aventis Docket No. USAV2003/0073 US NP



Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3 Attorney Docket Number USAV2003/0073 - US - NP

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/747,994
				Filing Date	12-30-2003
				First Named Inventor	PARKAR, et al.
				Group Art Unit	Not Yet Known
				Examiner Name	Not Yet Known
Sheet	1	of	3	Attorney Docket Number	USAV2003/0073 - US - NP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/747,994
Filing Date	12-30-2003
First Named Inventor	PARKAR, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	USA2003/0073 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ARIMURA Akinori et al., Prevention Of Allergic Inflammation By A Novel Prostaglandin Receptor Antagonist, S-5751, The Journal Of Pharmacology And Experimental Therapeutics, (2001), Vol. 298, No. 2, pp. 411 - 419	
		ARMSTRONG Roma A., Platelet Prostanoid Receptors, Pharmacol. Ther., (1996), Vol. 72, No. 3, pp. 171 - 191	
		BRIGHTLING C. E. et al., New Insights Into The Role Of The Mast Cell In Asthma, Clin. Exp. Allergy, (2003), Vol. 33, pp. 550 - 556	
		COLEMAN Robert A. et al., International Union Of Pharmacology Classification Of Prostanoid Receptor: Properties, Distribution, And Structure Of The Receptors And Their Subtypes, Pharmacological Reviews, (1994), Vol. 46, No. 2, pp. 205 - 229	
		DOYLE William J. et al., Physiologic Responses To Intranasal Dose-Response Challenges With Histamine, Methacholine, Bradykinin, And Prostaglandin In Adult Volunteers With And Without Nasal Allergy, Journal Of Allergy And Clinical Immunology, (1990), Vol. 86, pp. 924 - 935	
		HIRATA Masakazu et al., Molecular Characterization Of A Mouse Prostaglandin D Receptor And Functional Expression Of The Cloned Gene, Proc. Nat'l. Acad. Sci. USA, (1994), Vol. 91, pp. 11192 - 11196	
		HOLGATE Stephen T. et al., Bronchial Epithelium As A Key Regulator Of Airway Allergen Sensitization And Remodeling In Asthma, Am. J. Respir. Crit. Care Med., (2000), Vol. 162, pp. S113 - S117	
		KOBAYASHI Takuwa et al., Amino Acid Residues Conferring Ligand Binding Properties Of Prostaglandin I And Prostaglandin D Receptors, The Journal Of Biological Chemistry, (2000), Vol. 276, No. 32, pp. 24294 - 24303	
		LEWIS Robert A. et al., Prostaglandin D2 Generation After Activation Of Rat And Human Mast Cells With Anti-IgE, The Journal Of Immunology, (1982), Vol. 129, No. 4, pp. 1627 - 1631	
		MATSUOKA Toshiyuki et al., Prostaglandin D2 As A Mediator Of Allergic Asthma, Science, (2000), Vol. 287, pp. 2013 - 2019	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please place a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/747,994
Filing Date	12-30-2003
First Named Inventor	PARKAR, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	USA2003/0073 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NARUMIYA Shuh et al., Structure And Function Of Prostanoid Receptors, Journal Of Lipid Mediators, (1993), Vol. 6, pp. 155 - 161	
		NEGISHI Manabu et al., Prostanoid Receptors And Their Biological Actions, Prog. Lipid Res., (1993), Vol. 32, No. 4, pp. 417 - 434	
		ROBERTS L. Jackson et al., Increased Production Of Prostaglandin D2 In Patients With Systemic Mastocytosis, The New England Journal Of Medicine, (1980), Vol. 303, No. 24, pp. 1400 - 1404	
		WRIGHT D. Hamish et al., A Novel Biological Role For Prostaglandin D2 Is Suggested By Distribution Studies Of The Rat DP Prostanoid Receptor, European Journal Of Pharmacology, (1999), Vol. 377, pp. 101 - 115	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.